PAX8 and renal cell carcinoma: Galli et al. considered the PAX8 TF as a candidate oncogene in renal cell carcinoma (RCC) and demonstrated that this TF activates the expression of metabolic genes, including ceruloplasmin, by binding distal enhancer elements and recruiting histone acetylation activity [63].